Search Result

Results for "

carotid

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (4) Adrenergic Receptor (1) Aldehyde Dehydrogenase (ALDH) (1) Annexin A (1) Apoptosis (4) Endogenous Metabolite (1) Endothelin Receptor (2) Factor VIIa (1) Factor Xa (1) Flavivirus (3) Glutathione Reductase (1) Interleukin Related (1) MDM-2/p53 (1) NF-κB (4) p38 MAPK (1) Phosphodiesterase (PDE) (1) Prostaglandin Receptor (1) Reactive Oxygen Species (1) Ser/Thr Protease (3) TNF Receptor (3)
By Research Areas:	Cancer (5) Cardiovascular Disease (10) Infection (3) Inflammation/Immunology (6) Neurological Disease (6)

By Targets:

5-HT Receptor (4)

Adrenergic Receptor (1)

Aldehyde Dehydrogenase (ALDH) (1)

Annexin A (1)

Apoptosis (4)

Endogenous Metabolite (1)

Endothelin Receptor (2)

Factor VIIa (1)

Factor Xa (1)

Flavivirus (3)

Glutathione Reductase (1)

Interleukin Related (1)

MDM-2/p53 (1)

NF-κB (4)

p38 MAPK (1)

Phosphodiesterase (PDE) (1)

Prostaglandin Receptor (1)

Reactive Oxygen Species (1)

Ser/Thr Protease (3)

TNF Receptor (3)

By Research Areas:

Cancer (5)

Cardiovascular Disease (10)

Infection (3)

Inflammation/Immunology (6)

Neurological Disease (6)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B1735

Picotamide	Prostaglandin Receptor	Cardiovascular Disease
Picotamide is a combined inhibitor of thromboxane A2 (TxA2) synthase and receptor. Picotamide has antiplatelet activity. Picotamide promotes the reduction of microalbuminuria and the inhibition of growth of carotid plaques in diabetes. Picotamide can be used for researching acute or chronic cardiovascular diseases .

HY-114511

BMS-593214	Factor VIIa	Cardiovascular Disease
BMS-593214 is an active site-directed factor (F) VIIa inhibitor. BMS-593214 shows antithrombotic and antihaemostatic properties. BMS-593214 is a direct competitive inhibitor of human FVIIa and a non-competitive inhibitor of Viia-activated substrate FX. BMS-593214 prevents electroinduced carotid artery thrombosis (AT) and wire induced vena cava thrombosis (VT) .

HY-120657

9-PAHSA	Endogenous Metabolite	Cardiovascular Disease Inflammation/Immunology
9-PAHSA is an orally available anti-inflammatory lipid that lowers blood sugar and reduces inflammation. 9-PAHSA also improved carotid vascular calcification and attenuates cardiac hypertrophy and dysfunction in db/db mice. 9-PAHSA increases the viability of steatosis primary mouse hepatocytes (PMH). 9-PAHSA can be used in research on diabetes, inflammation, and cardiovascular disease .

HY-B1658A

Frovatriptan succinate hydrate (R)-Frovatriptan succinate hydrate; SB 209509 succinate hydrate; VML 251 succinate hydrate	5-HT Receptor	Neurological Disease
Frovatriptan succinate hydrate ((R)-Frovatriptan succinate hydrate) is a potent, high affinity, selective and orally active 5-HT_1B (pK₅₀ of 8.2) and 5-HT_1D receptor agonist. Frovatriptan succinate hydrate exhibits >10-fold selectivity for 5-HT_1B and 5-HT_1D over 5-HT_1A, 5-HT_1F, and 5-HT₇ and >1000-fold selectivity over other 5-HT, dopamine, histamine H₁, and α1-adrenoceptor. Frovatriptan succinate hydrate has the potential for migraine research .

HY-119883

A-61603 (free base）	Adrenergic Receptor	Neurological Disease
A-61603 free base is a potent adrenergic receptor agonist. A-61603 free base reduces carotid artery conductance in anesthetized pigs mediated by α1 and α2 adrenergic receptors (pEC₅₀=7.25). A-61603 free base can be used as a probe to study adrenergic function .

HY-122237

ATZ-1993	Endothelin Receptor	Cardiovascular Disease
ATZ-1993 is an orally active, nonpeptide endothelin receptor subtype Aand endothelin receptor subtype B antagonist with pK_i values of 8.69, 7.20, respectively. ATZ-1993 has the potential for the research of intimal hyperplasia after balloon denudation of the carotid artery .

HY-116262

SCH 51866	Phosphodiesterase (PDE)	Cardiovascular Disease Inflammation/Immunology
SCH 51866 is a potent, selective and orally active inhibitor of PDE1 (IC₅₀=70 nM) and PDE5 (IC₅₀=60 nM). SCH 51866 inhibits collagen-induced aggregation of human washed platelets (IC₅₀=10 μM), prevents neointimal formation in balloon catheter-injured carotid arteries of spontaneously hypertensive rats (SHR), and reduces blood pressure in SHR. SCH 51866 can be used in the study of hypertension .

HY-19210

SB-209670	Endothelin Receptor	Cardiovascular Disease
SB-209670 is an extremely potent and highly specific non-peptide, subnanomolar endothelin (ET) receptor antagonist. SB 209670 selectively inhibits binding of 125I-labeled ET-1 to cloned human ET receptor subtypes ETA and ETB (K_i=0.2 and 18 nM, respectively). SB 209670 produces a dose-dependent reduction in blood pressure in hypertensive rats, protects from ischemia-induced neuronal degeneration in a gerbil stroke model, and attenuates neointima formation following rat carotid artery balloon angioplasty .

HY-A0039

Eletriptan UK-116044	5-HT Receptor	Neurological Disease Inflammation/Immunology
Eletriptan (UK-116044) is a highly selective and orally active serotonin 5-HT_1B and 5-HT_1D receptor agonist, with pK_i values of 8.0 and 8.9, respectively. Eletriptan has inhibitory effects on markers of neurogenic inflammation in rats. Eletriptan can be used for researching migraine .

HY-B1658B

Frovatriptan succinate (R)-Frovatriptan succinate; SB 209509 succinate; VML 251 succinate	5-HT Receptor	Neurological Disease
Frovatriptan succinate ((R)-Frovatriptan succinate) is a potent, high affinity, selective and orally active 5-HT_1B (pK₅₀ of 8.2) and 5-HT_1D receptor agonist. Frovatriptan succinate exhibits >10-fold selectivity for 5-HT_1B and 5-HT_1D over 5-HT_1A, 5-HT_1F, and 5-HT₇ and >1000-fold selectivity over other 5-HT, dopamine, histamine H₁, and α1-adrenoceptor. Frovatriptan succinate has the potential for migraine research .

HY-B1658AR

Frovatriptan succinate hydrate (Standard)	5-HT Receptor	Neurological Disease
Frovatriptan (succinate hydrate) (Standard) is the analytical standard of Frovatriptan (succinate hydrate). This product is intended for research and analytical applications. Frovatriptan succinate hydrate ((R)-Frovatriptan succinate hydrate) is a potent, high affinity, selective and orally active 5-HT1B (pK50 of 8.2) and 5-HT1D receptor agonist. Frovatriptan succinate hydrate exhibits >10-fold selectivity for 5-HT1B and 5-HT1D over 5-HT1A, 5-HT1F, and 5-HT7 and >1000-fold selectivity over other 5-HT, dopamine, histamine H1, and α1-adrenoceptor. Frovatriptan succinate hydrate has the potential for migraine research .

HY-B0190

Nafamostat	Flavivirus TNF Receptor NF-κB Apoptosis Ser/Thr Protease	Infection Cancer
Nafamostat, an anticoagulant, is a synthetic serine protease inhibitor. Nafamostat has anticancer and antivirus effect. Nafamostat induce apoptosis by up-regulating the expression of tumor necrosis factor receptor-1 (TNFR1). Nafamostat can be used in the development of the pathological thickening of the arterial wall .

HY-B0190A

Nafamostat mesylate Maximum Cited Publications 12 Publications Verification FUT-175	Flavivirus TNF Receptor NF-κB Apoptosis Ser/Thr Protease	Infection Cancer
Nafamostat mesylate (FUT-175), an anticoagulant, is a synthetic serine protease inhibitor. Nafamostat mesylate has anticancer and antivirus effect. Nafamostat mesylate induce apoptosis by up-regulating the expression of tumor necrosis factor receptor-1 (TNFR1). Nafamostat mesylate can be used in the development of the pathological thickening of the arterial wall .

HY-B0190B

Nafamostat hydrochloride	Flavivirus TNF Receptor NF-κB Apoptosis Ser/Thr Protease	Infection Cancer
Nafamostat hydrochloride, an anticoagulant, is a synthetic serine protease inhibitor. Nafamostat hydrochloride has anticancer and antivirus effect. Nafamostat hydrochloride induces apoptosis by up-regulating the expression of tumor necrosis factor receptor-1 (TNFR1). Nafamostat hydrochloride can be used in the development of the pathological thickening of the arterial wall .

HY-144658

FXIa-IN-8	Factor Xa	Cardiovascular Disease
FXIa-IN-8 is a potent and selective FXIa inhibitor with an IC₅₀ of 14.2 nM. FXIa-IN-8 shows antithrombotic activity without increasing the bleeding risk and obvious toxicitysup>[1].

HY-P99171

Gevokizumab	Interleukin Related	Inflammation/Immunology Cancer
Gevokizumab is a potent anti-IL-1β antibody, negatively modulates IL-1β signaling through an allosteric mechanism. Gevokizumab selectively decreases the binding affinity of IL-1β for the IL-1 receptor type I (IL-1RI) signaling receptor instead of IL-1 counter-regulatory decoy receptor (IL-1 receptor type II) .

HY-126849

3-Morpholinosydnonimine SIN-1; Linsidomine	MDM-2/p53 Reactive Oxygen Species Apoptosis Annexin A Glutathione Reductase	Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
3-Morpholinosydnonimine (SIN-1) is a spontaneous ROS/RNS generator and peroxynitrite donor. 3-Morpholinosydnonimine induces oxidative stress-induced chondrocyte apoptosis and necrosis. 3-Morpholinosydnonimine inhibits the migration, proliferation and neointima formation of vascular smooth muscle cells by inhibiting the expression of annexin A2. In addition, low doses of 3-Morpholinosydnonimine shows protective effects on Zn ²⁺ treated nerve cells .

HY-76006

3-Hydroxybenzaldehyde M-Hydroxybenzaldehyde	Aldehyde Dehydrogenase (ALDH) NF-κB p38 MAPK	Cardiovascular Disease Inflammation/Immunology
3-Hydroxybenzaldehyde (3-HBA) is a precursor compound for phenolic compounds like Protocatechuic aldehyde (PCA) (HY-N0295). 3-Hydroxybenzaldehyde, produced by 3-hydroxybenzyl-alcohol dehydrogenase, is a substrate of aldehyde dehydrogenase (ALDH) in rats and humans. 3-Hydroxybenzaldehyde has vasculoprotective effects in vitro and in vivo. 3-Hydroxybenzaldehyde is proming for research of atherosclerosis .

Cat. No.	Product Name	Target	Research Area

HY-P3973

Thrombostatin cont-1	Peptides	Others
Thrombostatin cont-1 is an analogue of thrombostatin, which is a a bradykinin metabolite. Thrombostatin could decrease platelet activation in the canine carotid artery model of balloon angioplasty (BA) injury .

HY-P3082

SKF 106760	Peptides	Cardiovascular Disease
SKF 106760 is a potent platelet fibrin receptor (glycoprotein IIb/IIIa) antagonist with significant antiplatelet and antithrombotic activities. SKF 106760 inhibits platelet aggregation in dogs in vitro and prevents thrombus formation in stenotic carotid arteries. SKF 106760 has also shown elimination effects against aspirin-resistant thrombi that develop in the setting of high-grade stenosis .

Cat. No.	Product Name	Target	Research Area

HY-P99171

Gevokizumab	Interleukin Related	Inflammation/Immunology Cancer
Gevokizumab is a potent anti-IL-1β antibody, negatively modulates IL-1β signaling through an allosteric mechanism. Gevokizumab selectively decreases the binding affinity of IL-1β for the IL-1 receptor type I (IL-1RI) signaling receptor instead of IL-1 counter-regulatory decoy receptor (IL-1 receptor type II) .

9-PAHSA	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Other Diseases Endogenous metabolite Disease Research Fields	Endogenous Metabolite
9-PAHSA is an orally available anti-inflammatory lipid that lowers blood sugar and reduces inflammation. 9-PAHSA also improved carotid vascular calcification and attenuates cardiac hypertrophy and dysfunction in db/db mice. 9-PAHSA increases the viability of steatosis primary mouse hepatocytes (PMH). 9-PAHSA can be used in research on diabetes, inflammation, and cardiovascular disease .

3-Hydroxybenzaldehyde M-Hydroxybenzaldehyde	Cardiovascular Disease Structural Classification Monophenols Microorganisms other families Classification of Application Fields Ketones, Aldehydes, Acids Source classification Phenols Plants Disease Research Fields	Aldehyde Dehydrogenase (ALDH) NF-κB p38 MAPK
3-Hydroxybenzaldehyde (3-HBA) is a precursor compound for phenolic compounds like Protocatechuic aldehyde (PCA) (HY-N0295). 3-Hydroxybenzaldehyde, produced by 3-hydroxybenzyl-alcohol dehydrogenase, is a substrate of aldehyde dehydrogenase (ALDH) in rats and humans. 3-Hydroxybenzaldehyde has vasculoprotective effects in vitro and in vivo. 3-Hydroxybenzaldehyde is proming for research of atherosclerosis .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks